StreetInsider.com News Articles

Form 424B3 CDT Equity Inc.

Fri, 18 Sep 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260918/27081318.html

Form 8-K CDT Equity Inc. For: Sep 14

Fri, 18 Sep 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260918/27081296.html

Form 424B3 CDT Equity Inc.

Fri, 18 Sep 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260918/27080870.html

CDT Equity partners with QIMA to test tapinarof drug combinations

Fri, 18 Sep 2026 06:30:27 -0400

CDT Equity Inc. (Nasdaq: CDT) announced a partnership with QIMA Life Sciences, a preclinical dermatology contract research organization, to evaluate combinations of tapinarof in psoriasis and vitiligo, according to a press release dated Sept. 18, 2026.

Initial studies will focus on tapinarof, sold under the brand name VTAMA®, which is currently approved for plaque psoriasis and atopic dermatitis in the U.S. and Japan. CDT holds a portfolio of patents around tapinarof, including solid form and method-of-use patents in combination with other drugs. QIMA will test these combinations using skin tissue from psoriatic patients to assess the potential for a second-generation tapinarof

CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo

Fri, 18 Sep 2026 06:30:00 -0400

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a partnership with QIMA Life Sciences, a world leading preclinical dermatology CRO, to explore the potential of several of CDT’s assets in autoimmune skin diseases.

CDT plans to leverage QIMA’s unique access to human skin from both healthy donors and patients. The use of patient tissue offers the most clinically relevant data possible, providing rapid translation to clinic and providing potential license partners the highest level of confidence possible

CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo

Fri, 18 Sep 2026 06:30:00 -0400

Form EFFECT CDT Equity Inc.

Fri, 18 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260918/27077830.html

CDT Highlights Sarborg’s Application of Signature Intelligence and Quantum Computing Models to Mental Health

Thu, 10 Sep 2026 07:00:00 -0400

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 10, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the announcement from Sarborg Limited regarding the successful application of its patented Signature Intelligence and quantum computing models to mental health and neuropsychiatric drug discovery.

Mental health represents a significant global healthcare opportunity, with more than 1 billion people globally¹ living with a mental disorder and depression and anxiety alone estimated to cost the global economy approximately $1 trillion annually². Sarborg has developed a proprietary database of neuropsychiatric disease signatures, including depression,

CDT Highlights Sarborg’s Application of Signature Intelligence and Quantum Computing Models to Mental Health

Thu, 10 Sep 2026 07:00:00 -0400

CDT Equity resolves Nasdaq deficiencies, reports $23M market cap

Wed, 02 Sep 2026 06:01:09 -0400

CDT Equity Inc. (Nasdaq: CDT) announced that it has resolved all outstanding deficiencies with the Nasdaq Stock Market following recent share issuances and the exercise of pre-funded warrants.

As of August 31, 2026, the biopharmaceutical company had 13,693,866 shares of common stock issued and outstanding. Based on the closing price of CDT's common stock on that date, the company's market capitalization stood at approximately $23.0 million.

CDT reported stockholders' equity of approximately $103 million, as disclosed in its quarterly report on Form 10-Q for the quarter ended June 30, 2026. The company stated that the recent issuances and related corporate actions brought

CDT Provides Capital Update and Confirms No Nasdaq Deficiencies

Wed, 02 Sep 2026 05:00:00 -0400

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that, following the recent issuance of shares and the exercise of pre-funded warrants, the Company had 13,693,866 shares of Common Stock issued and outstanding as of August 31, 2026. Based on the closing price of CDT’s Common Stock on August 31, 2026, the Company had a market capitalisation of approximately $23.0 million.

CDT’s stockholders’ equity, as reported in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, was approximately $103

CDT Provides Capital Update and Confirms No Nasdaq Deficiencies

Wed, 02 Sep 2026 05:00:00 -0400

CDT’s stockholders’ equity, as reported in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, was approximately $103

CDT Equity names co-founder James Bligh as chief executive officer

Tue, 01 Sep 2026 08:00:43 -0400

CDT Equity Inc. (Nasdaq: CDT) announced the appointment of James Bligh, co-founder of the company, as chief executive officer, according to a press release dated Sept. 1, 2026.

Bligh co-founded Conduit Pharmaceuticals Limited, now CDT Equity, in 2019. Before that, he spent more than a decade advising on reverse takeovers, stock-market listings, initial public offerings, secondary fundraisings, and mergers and acquisitions. He has also held financial officer positions and served on corporate boards and audit-related committees.

Concurrent with the appointment, Dr. Andrew Regan has been named chief executive officer of Sarborg Limited, a quantum signature intelligence business in which CDT holds a

CDT Equity names co-founder James Bligh as chief executive officer

Tue, 01 Sep 2026 08:00:43 -0400

CDT Equity Inc. (Nasdaq: CDT) announced the appointment of James Bligh, co-founder of the company, as chief executive officer, according to a press release dated Sept. 1, 2026.

Concurrent with the appointment, Dr. Andrew Regan has been named chief executive officer of Sarborg Limited, a quantum signature intelligence business in which CDT holds a

CDT Equity names co-founder James Bligh as chief executive officer

Tue, 01 Sep 2026 08:00:43 -0400

CDT Equity Inc. (Nasdaq: CDT) announced the appointment of James Bligh, co-founder of the company, as chief executive officer, according to a press release dated Sept. 1, 2026.

Concurrent with the appointment, Dr. Andrew Regan has been named chief executive officer of Sarborg Limited, a quantum signature intelligence business in which CDT holds a

CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth

Tue, 01 Sep 2026 08:00:00 -0400

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 01, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced the appointment of James Bligh, co-founder of Conduit Pharmaceuticals Limited (now CDT), as Chief Executive Officer. Mr. Bligh brings extensive public-markets, corporate finance and transaction experience to the role and will lead the Company as it enters its next phase of growth and value creation. Dr. Andrew Regan has been appointed as CEO of Sarborg Limited.

Mr. Bligh co-founded Conduit Pharmaceuticals Limited in 2019 and has played an important role in the development and

CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth

Tue, 01 Sep 2026 08:00:00 -0400

Mr. Bligh co-founded Conduit Pharmaceuticals Limited in 2019 and has played an important role in the development and

CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

Fri, 28 Aug 2026 05:00:00 -0400

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that new solid forms and alternative crystal structures of its existing drug compounds, show enhanced physical property advantages, including improved stability, solubility, manufacturability, over existing forms of these compounds. These solid forms are patent-protected under the Company’s Substance of Matter IP and could support new formulations tailored to specific patient needs, prospectively increasing the commercial life of the underlying assets.

Following implementation of Sarborg’s Signature Intelligence to identify new potential uses for

CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

Fri, 28 Aug 2026 05:00:00 -0400

Following implementation of Sarborg’s Signature Intelligence to identify new potential uses for

CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

Fri, 28 Aug 2026 05:00:00 -0400

Following implementation of Sarborg’s Signature Intelligence to identify new potential uses for

CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

Fri, 28 Aug 2026 05:00:00 -0400

Following implementation of Sarborg’s Signature Intelligence to identify new potential uses for

CDT invests in Pep'd via SAFE note with $10M valuation cap

Tue, 25 Aug 2026 06:02:15 -0400

CDT Equity Inc. (NASDAQ: CDT) has entered into a Simple Agreement for Future Equity (SAFE) note with Pep'd Inc., a US-based peptide telehealth company, according to a press release from CDT.

The SAFE note carries a valuation cap of $10,000,000 and will automatically convert into shares of Safe Preferred Stock upon Pep'd closing an equity financing round, with the number of shares determined by Pep'd's capitalization at that time.

Pep'd is a telehealth and life sciences company that connects patients across all 50 US states with licensed clinicians for care in metabolic health, longevity, and aesthetics. The company also conducts peptide research

CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market

Tue, 25 Aug 2026 05:00:00 -0400

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a SAFE note with Pep'd Inc. (“Pep'd”), a US-based peptide company, expanding CDT's exposure to the growing US peptide market (the “Transaction”). Upon Pep’d closing an Equity Financing, this SAFE will automatically convert into a number of shares of Safe Preferred Stock, depending on the Pep’d Capitalization at that time and a Valuation Cap of $10,000,000.

The Transaction extends CDT's strategy of identifying and backing high-potential and science-driven assets,

CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market

Tue, 25 Aug 2026 05:00:00 -0400

The Transaction extends CDT's strategy of identifying and backing high-potential and science-driven assets,

CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market

Tue, 25 Aug 2026 05:00:00 -0400

The Transaction extends CDT's strategy of identifying and backing high-potential and science-driven assets,